^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-06753512

    i
    Other names: PF-06753512, PrCa VBIR, PF 6753512, PF-6753512 , VBIR-1
    Associations

    News

    Trials
    Company:
    Pfizer
    Drug class:
    CTLA4 inhibitor, Immunostimulant, IL-2 stimulant
    Related drugs:
    Associations

    News

    Trials
    over1year
    First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). (PubMed, J Immunother Cancer)
    PrCa VBIR overall demonstrated safety signals similar to other ICI combination trials; significant side effects were seen in some patients with BCR. It stimulated antigen-specific immunity across all cohorts and resulted in modest antitumor activity in patients with BCR without using ADT.
    P1 data • Clinical Trial,Phase I • Journal • Metastases
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    Imjudo (tremelimumab-actl) • sasanlimab (PF-06801591) • PF-06753512